相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件:
for future use below -18°C
- 保质期:
See instructions
- 英文名:
F9
- 库存:
常规产品有备货
- 供应商:
上海经科化学科技有限公司
- CAS号:
无
- 规格:
50ug/100ug/1mg
| 规格: | 50ug | 产品价格: | ¥10500.0 |
|---|---|---|---|
| 规格: | 100ug | 产品价格: | ¥13200.0 |
| 规格: | 1mg | 产品价格: | ¥61000.0 |

CATALOGUE NUMBER
PRO-353
SYNONYMS
INTRODUCTION
Lack of Factor-IX causes Hemophilia-B meaning Christmas Disease. Factor-IX has a N-terminus region which contains 12xGla residues which asist the calcium dpendant binding of Factor-IX to the phospholipid surface. Factor-IX is activated by either factor XIa or the factor VIIa/tissue factor/phospholipid complex. Cleavage yields the intermediate IXa, which is subsequently converted to the fully active form IXab.
Factor-IX binds initially to exosites on the factor XIa heavy chain, followed by interaction at the active site with subsequent bond cleavage. Coagulation factor IX is activated by interaction with the erythrocyte membrane, causing intrinsic coagulation. Chaperones & lectins act simultaniously to guarantee the proper folding of Factor-IX and the retention of mutant molecules. Human Factor IX, activated by either the Contact or Tissue Factor Pathway, is responsible for the activation of Factor X to Xa.
DESCRIPTION
SOURCE
PHYSICAL APPEARANCE
FORMULATION
SOLUBILITY
STABILITY
Please prevent freeze-thaw cycles.
PURITY
BIOLOGICAL ACTIVITY
HUMAN VIRUS TEST
SAFETY DATA SHEET
SDS
USAGE
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Human Factor-IX produced from fresh frozen human plasma is a glycosylated polypeptide chain having a molecular mass of 56 kDa.
Use of Human Hepatocytes to Investigate Blood Coagulation Factor
Coagulation is the complex process by which activation of plasmatic haemostasis proteins ends up with the generation of fibrin. Most of the plasma coagulation proteins are synthesized in hepatocytes. The aim of this chapter
Factor IX Gene Therapy for Hemophilia
Using gene therapy to produce systemic levels of human factor IX for the treatment of hemophilia B has been clinically evaluated using viral-based vectors. The efficacy of this approach has been limited because of immune responses
Ex Vivo Stromal Cell Electroporation of Factor IX cDNA for Treatment of Hemophilia B
Hemophilia B is an X-linked genetic disorder that typically results from chronic circulating deficiency of blood coagulation factor IX (FIX) (1). While the occurrence of hemophilia B is significantly less frequent than hemophilia A (factor
技术资料









